热门资讯> 正文

Mesobster报告称，由于Ryonspel销售强劲，第二季度收入激增66%

2025-10-07 12:34

Mesoblast (OTCPK:MEOBF) reported US$21.9M in gross revenue for the quarter ended September 30, 2025.
This marks a 66% increase compared to the previous quarter.
Growth driven by strong sales of Ryoncil (remestemcel-L-rknd).
Ryoncil is the first FDA-approved mesenchymal stromal cell therapy. It remains the only approved treatment for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).
Source: Press release

More on Mesoblast

Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript
Mesoblast Limited 2025 Q4 - Results - Earnings Call Presentation
Seeking Alpha’s Quant Rating on Mesoblast
Historical earnings data for Mesoblast
Financial information for Mesoblast

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。